Aprovasc 300/5mg Tablets
Each film-coated tablet contains Irbesartan/Amlodipine (as besilate) 150 mg/5 mg, 300 mg/5 mg and 300 mg/10 mg.
Irbesartan/amlodipine (Aprovasc) is an angiotensin-receptor blocker. As a result, these constituent drugs exert additive effects when coadministered. Therefore, it is for patients who cannot control their blood pressure on irbesartan or amlodipine monotherapy.
Use of Aprovasc 300mg/5mg tablets
APROVASC 300/5mg contains Irbesartan and Amlodipine per tablet. Amlodipine is an antihypertensive drug of class calcium-channel blockers used to manage hypertension and angina pectoris in Kenya. Irbesartan is an angiotensin II receptor antagonist. It contains hypertension, including the treatment of renal disease in hypertensive diabetic patients. Irbesartan is also under investigation in heart failure.
Irbesartan and Amlodipine:
Irbesartan: Mechanism of action: Irbesartan is a specific antagonist of angiotensin II receptors (AT1 subtype). The pharmacodynamic properties of each drug Irbesartan and Amlodipine provide an addition of antihypertensive effects. When administered in combination against the effect observed with both components separately. The AT1 receptor blocker and the calcium channel antagonist lower blood pressure by reducing peripheral resistance but blocking calcium flow and reducing vasoconstriction by angiotensin II are complementary mechanisms. Angiotensin II is an essential component of the renin-angiotensin system. It participates in the pathophysiology of hypertension and sodium homeostasis. Irbesartan does not require metabolic activation for its action. Irbesartan blocks the potent vasoconstriction and aldosterone secretion effects of angiotensin II by selective antagonism of angiotensin II receptors (AT1 subtype) in vascular smooth muscle cells and the adrenal cortex. Irbesartan has no agonist activity at the AT1 receptor and has a much higher affinity (more than 8 500 times) for the AT1 receptor than for the AT2 receptor. Irbesartan does not inhibit the enzymes that participate in the renin-angiotensin system, the angiotensin-converting enzyme (ACE), nor does it affect other hormone receptors or ion channels involved in the cardiovascular regulation of blood pressure and sodium homeostasis. AT1 receptor blockade caused by irbesartan disrupts the feedback loop within the renin-angiotensin system resulting in increases in plasma renin and angiotensin II levels.
- Pregnancy: There are no adequate and well-controlled studies in pregnant women. Irbesartan/Amlodipine (Aprovasc) is contraindicated during pregnancy. Irbesartan/Amlodipine(Aprovasc) must not be administered to women of childbearing potential unless adequate contraception is used. When pregnancy is detected, Irbesartan/Amlodipine (Aprovasc) shall be discontinued as soon as possible. (See Contraindications and Warnings).
- Lactation: Irbesartan/Amlodipine (Aprovasc) is contraindicated during lactation.
Get more products and services from DMRC KENYA right here.
For a more interactive platform, be sure to find us on Facebook by clicking right here.